Palvella Therapeutics (PVLA) Preferred Stock Liabilities (2022 - 2023)
Palvella Therapeutics (PVLA) reported Preferred Stock Liabilities of $70.6 million for Q4 2023, little changed year-over-year from $70.6 million in Q4 2022, and little changed on a QoQ basis from $70.6 million in Q4 2022.
Palvella Therapeutics (PVLA) has 2 years of Preferred Stock Liabilities data on file, last reported at $70.6 million in Q4 2023.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $70.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $70.6 million (changed 0.0% YoY) and the FY2023 annual result came in at $70.6 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities was little changed at $70.6 million in Q4 2023 per PVLA's latest filing, from $70.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $70.6 million in Q4 2022 and bottomed at $70.6 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 70.60 Mn |
| Dec 31, 2022 | 70.60 Mn |